Aktis Oncology (NASDAQ:AKTS) Shares Climb 5.7% – Here’s What Happened

Shares of Aktis Oncology (NASDAQ:AKTS) traded up 5.7% during mid-day trading on Tuesday. The stock traded as high as $17.31 and last traded at $17.31. 164,301 shares changed hands during trading, a decline of 54% from the average daily volume of 354,639 shares. The stock had previously closed at $16.37.

Analysts Set New Price Targets

A number of research firms recently commented on AKTS. BMO Capital Markets initiated coverage on shares of Aktis Oncology in a report on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 price target on the stock. Wall Street Zen downgraded Aktis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Weiss Ratings lowered Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, October 2nd. Oppenheimer initiated coverage on Aktis Oncology in a research report on Wednesday, September 9th. They set an “outperform” rating and a $40.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $35.00 price target on shares of Aktis Oncology in a research note on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $35.62.

Aktis Oncology Price Performance

The firm’s 50 day moving average price is $18.96 and its two-hundred day moving average price is $20.84. The stock has a market cap of $878.17 million and a PE ratio of -19.84.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings results on Thursday, November 12th. The technology company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.07). The company had revenue of $3.91 million for the quarter, compared to the consensus estimate of $4.02 million. Analysts anticipate that Aktis Oncology will post -1.84 earnings per share for the current year.

Institutional Investors Weigh In On Aktis Oncology

Several institutional investors have recently made changes to their positions in the stock. GK Wealth Management LLC purchased a new position in shares of Aktis Oncology in the third quarter valued at $26,000. Silver Grove Financial Group Inc. purchased a new stake in Aktis Oncology during the 3rd quarter worth about $28,000. Global Retirement Partners LLC boosted its stake in Aktis Oncology by 289.1% in the 3rd quarter. Global Retirement Partners LLC now owns 1,537 shares of the technology company’s stock worth $30,000 after purchasing an additional 1,142 shares during the period. State of Wyoming bought a new position in Aktis Oncology in the 2nd quarter worth about $32,000. Finally, Russell Investments Group Ltd. grew its holdings in Aktis Oncology by 8.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,391 shares of the technology company’s stock valued at $163,000 after buying an additional 637 shares in the last quarter. Hedge funds and other institutional investors own 28.84% of the company’s stock.

About Aktis Oncology

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.